Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine

Exclusion Criteria

• •1. Self-reported vaccination with influenza vaccine for the current season
• •2. Vaccination with any vaccine within the one month period prior to study enrollment or intent to receive any other vaccine during the study period
• •3. History of hypersensitivity to any influenza vaccine components including thimerosal or egg
• •4. History of Guillain-Barre syndrome
• •5. History of avoidance of egg and/or egg based products for any reason
• •6. Acute febrile illness within the week prior to immunization - immunization deferred until illness resolved
• •7. Consumption of supplements or food products containing LGG or probiotics for 28 days prior to the start of the study or consumption of yogurt that has the "live and active cultures" seal
• •8. Known or suspected allergies to probiotics, Lactobacillus, microcrystalline cellulose, gelatin, or antibiotics that may be used to treat LGG bacteremia or infection
• •9. Received oral or parenteral antibiotics within 4 weeks of enrollment or prescribed antibiotics on the day of enrollment
• •10. Drug or alcohol abuse within the previous 12 months
• •11. Hospitalization, major surgery or endoscopy within the last 3 months
• •12. Scheduled hospital admission within 3 months of enrollment
• •13. Resident of a nursing home or rehabilitation center
• •14. Presence of any of the following:
• •1. Grade 2 or higher abnormal vital signs or abnormalities on physical exam
• •2. Indwelling catheter or implanted hardware/prosthetic device or feeding tube
• •3. Current or within the last 2 years, any episode of bowel leak, acute abdomen, diverticulitis, bloody bowel movements or peptic ulcer disease, including any surgical procedure or current prescription medications for any of these conditions
• •4. Current or within the last 4 weeks, active bowel disease such as an episode of infectious or non-infectious diarrhea, constipation or vomiting lasting more than 12 hours or current prescription medications for any of these conditions
• •5. Any history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, history of disease or current prescription medication for any of these conditions
• •6. Any history of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease
• •7. Underlying structural heart disease such as abnormal native heart valve replacement, Stage IV congestive heart failure
• •8. History of peripheral vascular disease or stroke
• •9. Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy, neutrophil count \<500/mm\^3, or an anticipated drop in the neutrophil count to \<500/mm\^3 or active or planned chemotherapy or radiotherapy
• •10. History of collagen vascular or autoimmune disease
• •11. End stage renal disease
• •12. History of chronic obstructive pulmonary disease or asthma
• •13. Diabetes or thyroid disease
• •14. Active tuberculosis (TB), defined as undergoing a work up for suspected active TB infection or currently on treatment for active TB
• •15. Positive drug or alcohol testing at screening or positive breathalyzer at baseline or an unwillingness to undergo drug and alcohol testing
• •16. Abnormal laboratory tests defined as any of the following:
• •1. White blood cell (WBC) \<3.3 or \> 12.0 K/microliter
• •2. Platelets \< 125 K/microliter
• •3. Hemoglobin Males: \< 12.0 g/dL; Females \< 11.0 g/dL
• •4. Creatinine \> 1.8 mg/dL
• •5. Blood Urea Nitrogen (BUN)\> 27 mg/dL
• •6. Aspartate aminotransferase (AST) \> 1.25 ULN
• •7. Alanine aminotransferase \> 1.25 ULN
• •8. Alkaline phosphatase \> 2.0 ULN
• •9. Bilirubin (total) \> 1.5 ULN
• •10. Glucose (nonfasting) \> 126 mg/dL
• •11. Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody
• •17. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study or would make it unlikely the subject could complete the study
• •\-